VRTX vs XLK
Vertex Pharmaceuticals Inc (VRTX) versus Technology Select Sector SPDR® Fund (XLK) — a side-by-side from cached financials, not a winner call.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Technology Select Sector SPDR® Fund (XLK) common stock listed on US.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
XLK does not have a complete income-statement cache yet.
VRTX currently screens at market cap $106.87B and trailing P/E 29.7. XLK currently screens at market cap $0.
Not investment advice. Open the VRTX and XLK stock pages for the full models.
Not investment advice.